Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$123.46 USD

123.46
1,033,841

-3.67 (-2.89%)

Updated May 24, 2024 04:00 PM ET

After-Market: $123.49 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Expands Collaboration With CRISPR, Acquires Exonics

by Zacks Equity Research

Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.

Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

by Zacks Equity Research

Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 47.81% and 0.11%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences Plunges After DMD Study Data Readout

by Zacks Equity Research

Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.

Indrajit Bandyopadhyay headshot

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

by Indrajit Bandyopadhyay

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

Sarepta Therapeutics (SRPT) Down 17.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta (SRPT) Reports Positive Interim Results for DMD Drug

by Zacks Equity Research

Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.

Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up

by Zacks Equity Research

Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.

Sarepta (SRPT) Jumps: Stock Rises 8.3%

by Zacks Equity Research

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

    Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review

    by Zacks Equity Research

    FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.

    Implied Volatility Surging for Sarepta (SRPT) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.

    Ekta Bagri headshot

    4 Biotechs That Are Potential Buyouts Post Celgene Deal

    by Ekta Bagri

    We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

    Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

    by Zacks Equity Research

    Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

    Sarepta Stock More Than Doubles This Year So Far: Here's Why

    by Zacks Equity Research

    Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

    Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Sarepta Therapeutics (SPRT) stock based on the movements in the options market lately.

    Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up

    by Zacks Equity Research

    Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.

    Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -64.71% and -0.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

    by Zacks Equity Research

    Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

    Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns

    by Zacks Equity Research

    Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.

      Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect

      by Zacks Equity Research

      Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Sarepta Announces Agreement With Lysogene for Gene Therapy

      by Zacks Equity Research

      Sarepta Therapeutics (SRPT) signs license agreement with France-based Lysogene to boost its gene therapy portfolio.

        Sweta Killa headshot

        Should iShares Morningstar Small-Cap Growth ETF (JKK) Be on Your Investing Radar?

        by Sweta Killa

        Style Box ETF report for JKK